Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor by Carolyn E. Behrendt et al.
“ﬁmmu-04-00036” — 2013/2/19 — 20:33 — page 1 — #1
ORIGINAL RESEARCH ARTICLE
published: 21 February 2013
doi: 10.3389/ﬁmmu.2013.00036
Donor killer immunoglobulin-like receptor genes and
reactivation of cytomegalovirus after HLA-matched
hematopoietic stem-cell transplantation: HLA-C allotype
is an essential cofactor
Carolyn E. Behrendt1*, Ryotaro Nakamura 2, Stephen J. Forman 2 and JohnA. Zaia 3
1 Division of Biostatistics and Epidemiology, City of Hope, Duarte, CA, USA
2 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA
3 Department of Virology, Beckman Research Institute of the City of Hope, Duarte, CA, USA
Edited by:
Lewis L. Lanier, University of
California San Francisco, USA
Reviewed by:
Hugh Reyburn, Spanish National
Research Council, Spain
Jeffrey S. Miller, University of
Minnesota, USA
Karl-Johan Malmberg, Oslo University
Hospital, Norway
*Correspondence:
Carolyn E. Behrendt, Division of
Biostatistics and Epidemiology, City of
Hope, 1500 East Duarte Road, Duarte,
CA 91010, USA.
e-mail: cbehrendt@coh.org
Natural killer (NK) cells whose killer immunoglobulin-like receptors (KIRs) recognize
human leukocyte antigen (HLA) ligand are “licensed” for activity. In contrast, non-
licensed NK cells display KIRs for which ligand is absent from the self genotype and are
usually hyporesponsive. Surprisingly, non-licensed cells are active in tumor control after
hematopoietic stem-cell transplantation (HSCT) and dominate NK response to murine
cytomegalovirus (CMV) infection. From those reports, we hypothesized that control of
human CMV early after HSCT is inﬂuenced by donor KIR genes whose HLA ligand is
absent-from-genotype of HLA-matched donor and recipient. To investigate, we studied
CMV reactivation through Day 100 after grafts involving CMV-seropositive donor and/or
recipient. A multivariate proportional rates model controlled for variability in surveillance
and established covariates including acute graft-versus-host disease; statistical signiﬁcance
was adjusted for testing of multiple KIRs with identiﬁed HLA class I ligand (2DL1, 2DL2/3,
2DS1, 2DS2, full-length 2DS4, 3DL1/3DS1, 3DL2). AmongHSCT recipients (n = 286), CMV
reactivation-free survival time varied with individual donor KIR genes evolutionarily speciﬁc
for HLA-C: when ligand was absent from the donor/recipient genotype, inhibitory KIRs
2DL2 (P < 0.0001) and 2DL1 (P = 0.015) each predicted inferior outcome, and activating
KIRs 2DS2 (P < 0.0001), 2DS1 (P = 0.016), and 2DS4 (P = 0.016) each predicted superior
outcome. Otherwise, with ligand present-in-genotype, donor KIR genes had no effect. In
conclusion, early after HLA-matched HSCT, individual inhibitory and activating KIR genes
have qualitatively different effects on risk of CMV reactivation; unexpectedly, absence of
HLA-C ligand from the donor/recipient genotype constitutes an essential cofactor in these
associations. Being KIR- and HLA-C-speciﬁc, these ﬁndings are independent of licensing
via alternate NK cell receptors (NKG2A, NKG2C) that recognize HLA-E.
Keywords: cytomegalovirus, hematopoietic stem-cell transplantation, HLA, killer Ig-like receptors, natural killer
cells
INTRODUCTION
Early after hematopoietic stem-cell transplantation (HSCT), the
repertoire of natural killer (NK) cells in the recipient is less
differentiated than in the donor, skewed toward expression of
inhibitory receptor CD94–NKG2A and against expression of killer
immunoglobulin-like receptors (KIR; Bjørklund et al., 2010).
Within 8–12 weeks after HSCT, however, the proportion of KIR+
NK cells gradually normalizes through cell differentiation, and the
responsiveness of KIR+ cells comes to depend on the presence
of corresponding human leukocyte antigen (HLA) ligand (Haas
et al., 2011). NK cell expansions in response to cytomegalovirus
(CMV, either latent in the recipient or reactivated) preferentially
express activating receptor NKG2C- and HLA-C-speciﬁc KIRs
that have ligand present-in-genotype (Kuijpers et al., 2008; Della
Chiesa et al., 2012; Foley et al., 2012a,b).
Under the tenets of NKcell licensing, thoseNKcells that express
inhibitory KIRs speciﬁc for self HLA ligands are functionally
competent (“licensed”; Orr and Lanier, 2010). Recent evidence
indicates that licensing also applies to NK cells that express acti-
vating KIRs (Fauriat et al., 2010). Non-licensed NK cells, on the
other hand, express inhibitory KIRs speciﬁc for HLA ligands that
are absent from the self genotype. Typically, these non-licensed
cells are hyporesponsive. Yet, early after HSCT, non-licensed NK
cells are clinically beneﬁcial: KIR ligand absent-from-genotype
has been associated with lower incidence of leukemic relapse after
HLA-matched HSCT (Hsu et al., 2005, 2006; Clausen et al., 2007;
Miller et al., 2007) and with better progression-free survival after
autologous HSCT for advanced neuroblastoma (Venstrom et al.,
2009). According to a recent report (Orr et al., 2010), non-licensed
cells dominate the NK response to murine CMV.
These published reports of NK cell functionality in the absence
of HLA ligand raise the question of whether control of human
CMV following HSCT can be mediated by donor KIRs whose
ligand is absent-from-genotype shared by HLA-matched donor
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and recipient. To test this possibility, we prospectively followed
HSCT recipients of grafts involving CMV-seropositive donor or
recipient. Previous studies of the role of KIRs in controlling
human CMV infection have mostly ignored the corresponding
HLA ligands (Chen et al., 2006; Cook et al., 2006; Zaia et al., 2009;
Gallez-Hawkins et al., 2011; Stern et al., 2011) or have studied the
absence of ligand for an aggregate group of inhibitory or activat-
ing KIRs (Hadaya et al., 2008; Stern et al., 2008). In contrast, our
study evaluated interactions between individual donor KIR genes
and the presence or absence of ligand genes in the donor/recipient
genotype, as risk factors for CMV reactivation through Day 100
after transplantation. Our analysis adjusted for the testing of
multiple hypotheses and took into account established covari-
ates, including method of CMV surveillance (Boeckh et al., 1997),
serologic status of donor and recipient (Ljungman et al., 2010),
onset of acute graft-versus-host disease (GVHD; Meyers et al.,
1986; Bacigalupo et al., 1995; Takenaka et al., 1997; Osarogiag-
bon et al., 2000; Yanada et al., 2003; Walker et al., 2007; Zaia
et al., 2009), use of sirolimus-based regimens for GVHD prophy-
laxis (Marty et al., 2007), and source of stem-cell graft (Guerrero
et al., 2012).
MATERIALS AND METHODS
ETHICS STATEMENT
The protocol for this observational cohort study was approved
in advance by the hospital’s institutional review board. Before
undergoing HSCT, all subjects gave written informed consent to
prospective follow-up and periodic blood sampling.
SUBJECTS
Eligible subjects were consecutive patients age 18 or older who
underwent a ﬁrst HLA-matched, allogeneic HSCT in 2000–2006
for underlying hematologic disease, receiving a graft of unma-
nipulated stem-cells from the peripheral blood or bone marrow
of a non-syngeneic sibling or unrelated donor. Further, only
those transplants in which donor and/or recipient was CMV-
seropositive prior to transplant were eligible for study. Exclusion
criteria for the current analysis were incomplete data [on donor
CMV serostatus (n = 5) or KIR genotype (n = 5)] or lack of stan-
dard CMV surveillance (due to reactivation detected immediately
before transplantation or other reason [n = 5]). CMV prophylaxis
was not utilized, but preemptive treatment with ganciclovir was
started upon detection of CMV reactivation in blood as previously
described (Zaia et al., 2009).
TYPING OF HLA AND KIR
Human leukocyte antigen typing of donors and recipients was per-
formed using one or more of the following methods: microbead
array assay with sequence-speciﬁc oligonucleotide probes (One
Lambda, Canoga Park, CA, USA), polymerase chain reaction
(PCR) ampliﬁcation with sequence-speciﬁc primers (Olerup SSP
AB, Saltsjöbaden, Sweden; Invitrogen Corporation, Carlsbad, CA,
USA), and sequence-based typing (Celera Corporation, Alameda,
CA, USA). HLA-C allotypes belong to two groups distinguished
by the amino acid residue at position 80; those allotypes with an
asparagine are termed group 1 or C1, and those with a lysine are
termed group 2 or C2 (Vilches and Parham, 2002).
For KIR typing, a previously described method (Sun et al.,
2004) was used to identify the functional, non-framework KIR
genes (2DS1-5; 3DS1; 2DL1-3 and 2DL5; 3DL1) and distinguish
full-length from deleted alleles of KIR2DS4 (Parham, 2005).
SURVEILLANCE FOR CMV REACTIVATION
At physician discretion, surveillance for CMV usually began as
close as possible to post-transplant Day 21 and generally contin-
ued until post-transplant Day 80–100. For surveillance, blood was
collected once or twice-weekly and assayed by shell vial culture
of whole blood (Gleaves et al., 1985). Whenever possible, plasma
from the same specimen was assayed by DNA-quantitative PCR,
limit of CMV detection: 200 genome copies/mL (Gallez-Hawkins
et al., 2005). As clinically indicated, bronchoalveolar lavage and tis-
sue biopsies were also tested for CMV by histopathology or tissue
culture. The day of CMV reactivation was deﬁned as the earliest
positive result by any of these methods.
STATISTICAL METHODS
The study endpoint was survival time free of CMV reactivation by
Day 100 after HSCT. Follow-up was censored when Day 100 post-
transplantation was reached or when CMV surveillance ended
earlier. In addition, cumulative incidences of CMV reactivation
and death without CMV were calculated as separate, competing
events (Fine and Gray, 1999).
Because use of PCR and frequency of testing could vary during
surveillance, it was necessary to consider each subject’s surveillance
as one or more periods, with a new period being started whenever
the conditions of surveillance changed, from twice-weekly to once
per week or from testing by PCR and viral culture to testing by cul-
ture alone. To ensure that surveillance would be at least 1 day in
duration even when CMV was detected in the subject’s ﬁrst spec-
imen, each surveillance period began on the eve of the ﬁrst assay
performed during that period. Multivariate analysis employed a
proportional rates model of time to CMV reactivation or death; a
robust sandwich covariance estimate took into account the intra-
cluster dependence arising when there were multiple observations
per subject (Lin et al., 2000).
The primary risk factors included the seven donor KIR genes
with an identiﬁed HLA ligand: KIR2DL1, KIR2DL2, KIR2DS1,
KIR2DS2, KIR2DS4, KIR3DS1, and universally present KIR3DL2.
Each KIR gene was analyzed as: present with its evolutionarily
speciﬁc ligand“present-in-genotype,” present with ligand“absent-
from-genotype,” and KIR gene absent. For those KIRs that belong
to pairs of alleles (2DL2/2DL3 and 3DL1/3DS1), one allele from
each pair was selected for the multivariate analysis; no associa-
tion was observed with the non-selected alleles when these were
included also. Because of biological evidence of delayed expression
of KIR2DL1 (Fischer et al., 2007), the analysis considered whether
associations with this KIR and with its homolog, KIR2DS1, were
time-dependent. To do so, we considered delays of 0–8 weeks
between day of transplantation and expression of these two KIRs;
for each KIR, the delay with the best ﬁt to the observed data
was retained in the model. In order to limit the study’s overall
Type I error rate to 5%, P values for the primary risk factors were
adjusted for multiple hypothesis testing using Holm’s method, a
more powerful version of the Bonferroni test (Holm, 1979).
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The model was adjusted for potentially confounding time-
dependent variables (onset of acuteGVHD that ultimately reached
grade II–IV (Przepiorka et al., 1995); twice-weekly versus once-
weekly surveillance) and ﬁxed covariates (donor’s CMV serostatus
and sibling versus unrelated status; female-to-male graft; source of
stem-cells; speciﬁc underlying disease; use of sirolimus for GVHD
prophylaxis; year of transplantation). Additional factors consid-
ered in the model were the recipient’s CMV serostatus and age at
transplantation, as well as donor KIR genes that have no identi-
ﬁed HLA class I ligand (2DS3, 2DS5, 2DL5). Because hematologic
diagnosis correlated so closely with intensity of conditioning reg-
imen and disease status at transplantation, the latter two variables
were dropped from multivariate analysis.
The assumption of proportionality of rates over time was veri-
ﬁed by examining Schoenfeld residuals generated by the model.
The ﬁt of the model to individual subjects was assessed by
examining dfbeta (weighted transformation of the score resid-
ual, approximating the change in a covariate’s effect when a given
observation is omitted).
RESULTS
SUBJECTS
The cohort included 286 subjects [age 43.0(11.6) years] who
underwent HLA-matched, allogeneic HSCT in which donor
and/or recipient was CMV-seropositive (Table 1). Acute GVHD
grade II–IV developed before or during follow-up in 154 (53.8%)
subjects and was already present at start of surveillance in 70
(24.5%) subjects.
Donor’s KIR genes, classiﬁed by presence or absence of HLA
ligand when applicable, are shown in Table 2. Being in linkage
disequilibrium, donor KIR2DL2 and KIR2DS2 were almost always
present together, but occasionally one or the other gene appeared
alone: 123 subjects had donors with KIR2DL2, of whom 120 had
donor KIR2DS2 also, and 123 subjects had donors with KIR2DS2,
of whom 120 had donor KIR2DL2 also.
SURVEILLANCE FOR CMV REACTIVATION
In nearly all (90.6%) subjects, surveillance began within the 7 days
before or after Day 21 post-transplantation. Usually, surveillance
was performed twice per week and utilized both viral culture and
DNA-quantitative PCR. However, in 28.7% of subjects, at least
some surveillance was by culture alone, and in 15.4% of subjects,
at least some surveillance was once per week.
At the close of surveillance by Day 100 post-transplantation,
cumulative incidences (standard deviation) of CMV reactivation
and of death not preceded by CMV disease or reactivation were
66.4(3.0) and 3.0(1.0)%, respectively. There were seven cases of
CMV disease [gastritis (n = 3), colitis (n = 2), or pneumonitis
(n = 2)], none of which contributed to a death. Instead, deaths
without prior CMV activity (n = 8) were attributed to acute
respiratory distress syndrome and/or multi-organ system failure
(n = 5), relapsed or progressive leukemia (n = 2), and veno-
occlusive disease of the liver (n = 1). Of subjects (n = 96) who
did not experience CMV reactivation or death, nearly all (86.5%)
continued surveillance through at least Day 80 post-HSCT.
Because cases of CMVreactivation so thoroughly outnumbered
deaths without prior reactivation (by a ratio of 182:8), the analysis
Table 1 | Characteristics of HSCT recipients and grafts (N = 286)
N (%)
RECIPIENT
Year of age at transplantation
18–39 103 (36.0)
40–59 160 (55.9)
60–68 23 (8.0)
Hematologic diagnosis
Leukemia 209 (73.1)
Acute lymphoid leukemia 53 (18.5)
Acute myeloid leukemia 91 (31.8)
Chronic lymphoid leukemia 3 (1.1)
Chronic myeloid leukemia 41 (14.3)
Myelodysplastic syndrome 21 (7.3)
Other 77 (26.9)
Hodgkin lymphoma 6 (2.1)
Multiple myeloma 4 (1.4)
Myeloproliferative disorder 7 (2.5)
Non-Hodgkin lymphoma 49 (17.1)
Severe aplastic anemia 11 (3.9)
Calendar year of transplantation
2000–2002 104 (36.4)
2003–2006 182 (63.6)
Prophylaxis for graft-versus-host disease
Sirolimus and tacrolimus 50 (17.5)
Tacrolimus and methotrexate 66 (23.1)
Mycophenolate mofetil-based regimen 95 (33.2)
Cyclosporin A and methotrexate 75 (26.2)
GRAFT
Donor type
Sibling 184 (64.3)
Unrelated 102 (35.7)
Source of graft
Peripheral blood 239 (83.6)
Bone marrow 47 (16.4)
Sex of donor, recipient
D female, R male 58 (20.3)
D female, R female 57 (19.9)
D male, R male 96 (33.6)
D male, R female 75 (26.2)
Pretransplant CMV serostatus of donor, recipient
D−, R+ 76 (26.6)
D+, R− 29 (10.1)
D+, R+ 181 (63.3)
CMV, cytomegalovirus; D, donor; HSCT, hematopoietic stem-cell transplant;
R, recipient.
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Table 2 | Donor KIR genes, by presence of HLA ligand in shared
genotype of donor and recipient pair (N = 286).
N (%)
Inhibitory KIR
2DL1
With C2 162 (56.7)
Without C2 114 (39.9)
No donor KIR2DL1 10 (3.5)
2DL2
With C1 103 (36.0)
Without C1 20 (7.0)
No donor KIR2DL2 163 (57.0)
2DL3
With C1 225 (78.7)
Without C1 38 (13.3)
No donor KIR2DL3 23 (8.0)
2DL5
Present 138 (48.3)
Absent 148 (51.7)
3DL1
With B-Bw4 152 (53.2)
Without B-Bw4 118 (41.3)
No donor KIR3DL1 16 (5.6)
3DL2 (universally present)
With A-3 and/or A-11 95 (33.2)
Without A-3 and/or A-11 191 (66.8)
Activating KIR
2DS1
With C2 61 (21.3)
Without C2 43 (15.0)
No donor KIR2DS1 182 (63.6)
2DS2
With C1 105 (36.7)
Without C1 18 (6.3)
No donor KIR2DS2 163 (57.0)
2DS3
Present 75 (26.2)
Absent 211 (73.8)
2DS4 (full-length allele)
With C*0501,C*1601 10 (3.5)
Without C*0501 or C*1601 121 (42.3)
No donor KIR2DS4 (full-length allele) 155 (54.2)
2DS5
Present 81 (28.3)
Absent 205 (71.7)
3DS1
With B-Bw4 61 (21.3)
Without B-Bw4 46 (16.1)
No donor KIR3DS1 179 (62.6)
of CMV reactivation-free survival closely approximated an analy-
sis of time to CMV reactivation. Moreover, had the eight subjects
who died without CMV reactivation been omitted from analysis,
the results would have been virtually unchanged (data not shown).
GENETIC ASSOCIATIONS WITH CMV REACTIVATION
In multivariate analysis (Table 3), ﬁve of the seven KIRs stud-
ied were associated with CMV reactivation, as follows. Inhibitory
KIR2DL2 and KIR2DL1 were independently associated with
increased likelihood of CMV reactivation, but only when the cor-
responding ligand was absent from the genotype shared by donor
and recipient. Of note, the association with KIR2DL2 was more
marked and began earlier than the association with KIR2DL1,
which did not begin until Day 49 post-HSCT. Likewise, activating
KIR2DS2, KIR2DS1, and KIR2DS4 (full-length allele) were each
associated with reduced likelihood of reactivation, but only when
the corresponding ligand was absent from the genotype. Of note,
the association with KIR2DS2 was more marked and began ear-
lier than the association with KIR2DS1, which did not begin until
Day 21. The protection against CMV reactivation associated with
KIR2DS4 (full-length allele), although signiﬁcant, was less marked
than that associated with KIR2DS2 and KIR2DS1.
Donor KIR genes without identiﬁed HLA class I ligand
(KIR2DS3,KIR2DS5,KIR2DL5) did not contribute to the ﬁt of the
model and were therefore omitted. When the model was limited
to the primary risk factors, adjusted only for whether surveillance
for CMV included PCR, the results were similar (data not shown).
Whether a KIR’s ligand was present in one or two gene copies did
not alter any of the associations (data not shown).
DISCUSSION
According to this study, the risk of CMV reactivation following
HLA-matched HSCT is associated with individual donor KIR
genes, but only when their evolutionarily speciﬁc HLA-C lig-
and is absent from the shared donor/recipient genotype. Our
results add to the evidence that non-licensed NK cells can play an
important role in host control of tumors (Hsu et al., 2005, 2006;
Clausen et al., 2007; Miller et al., 2007; Venstrom et al., 2009) and
infection, speciﬁcally murine CMV (Orr et al., 2010), with one
important difference. Unlike previous reports, our study suggests
that“presumably non-licensed”NK cells (inhibitory KIRswith lig-
and absent-from-genotype) are associated with worse, not better,
clinical outcome, while comparable activating KIRs (those with
ligand absent-from-genotype) have qualitatively opposite effects,
being associated with better, not worse, clinical outcome among
our subjects. Also, unlike studies in vitro (Kim et al., 2008; Fauriat
et al., 2010), our clinical study did not detect a dose effect from the
gene copy number of HLA ligand.
The chief limitation of our study is the lack of in vitro data, on
KIR expression in NK and T cells and on the licensing status of
KIR-bearing cells early after allogeneicHSCT.Conclusions can still
be drawn from these genotyping data, because a ligand absent-in-
genotype can be expected to be absent in expression also. Although
unstudied here, expression of NKG2A and NKG2C could not have
confounded our results: because our ﬁndings are KIR- and HLA-
C-speciﬁc, they are independent of licensing through NKG2A or
NKG2C, which recognize HLA-E.
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Table 3 | CMV reactivation-free survival after HLA-matched, allogeneic HSCT (N = 286).
Protection ← Rate ratio → Hazard
Risk factor Rate ratio (95% CI) P 0.05 0.1 0.2 0.5 1 2 5 10 20
Donor inhibitory KIR:
KIR2DL2
Without C1 7.97 (3.71, 17.1) <0.0001 - - - - - -•- - - - - -
With C1 1.17 (0.66, 2.09) NS - -◦- -
Absent 1.00
†KIR2DL1, starting Day 49 post-HSCT
Without C2 2.40 (1.39, 4.13) 0.015 - - -•- - -
With C2 1.03 (0.60, 1.75) NS - -◦- -
Absent 1.00
KIR3DL2
Without A-3 and/or A-11 1.06 (0.78, 1.43) NS - -◦- -
With A-3 and/or A-11 1.00
Donor activating KIR:
KIR2DS2
Without C1 0.05 (0.02, 0.13) <0.0001 -•- - - - - - - - -
With C1 0.59 (0.34, 1.04) NS - -◦- -
Absent 1.00
†KIR2DS1, starting Day 21 post-HSCT
Without C2 0.41 (0.24, 0.71) 0.016 - - -•- - -
With C2 0.68 (0.41, 1.16) NS - -◦- -
Absent 1.00
Full-length KIR2DS4
Without C*0501 or C*1601 0.61 (0.45, 0.83) 0.016 - - -•- - -
With C*0501 or C*1601 0.63 (0.27, 1.49) NS - -◦- - - -
Absent 1.00
KIR3DS1
Without B-Bw4 1.33 (0.76, 2.32) NS - -◦- -
With B-Bw4 1.66 (1.10, 2.49) NS - -◦- -
Absent 1.00
Covariates:
†Method of CMV surveillance, by Era 1.22 (0.61, 2.43)
Viral Culture plus PCR, 2000–2002 1.00
Viral Culture Alone, 2000–2002 3.15 (1.59, 6.25)
Viral Culture plus PCR, 2003–2006 0.29 (0.10, 0.89)
Viral Culture Alone, 2003–2006 1.22 (0.61, 2.43)
†Frequency of CMV surveillance
Twice per week 1.27 (0.77, 2.11)
Once per week 1.00
†Acute GVHD
Had occurred 1.73 (1.27, 2.36)
Had not occurred 1.00
CMV serostatus and type of donor
Seronegative sibling donor 2.00 (1.19, 3.37)
(Continued)
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Table 3 | Continued
Protection ← Rate ratio → Hazard
Risk factor Rate ratio (95% CI) P 0.05 0.1 0.2 0.5 1 2 5 10 20
Seropositive sibling donor 1.00
Seronegative unrelated donor 0.99 (0.66, 1.48)
Seropositive unrelated donor 1.07 (0.74, 1.57)
GVHD prophylaxis
Sirolimus and tacrolimus 0.37 (0.22, 0.60)
Other regimen 1.00
Female-to-male graft
Yes 1.34 (0.93, 1.92)
No 1.00
Leukemia/myelodysplastic syndrome
Yes 0.75 (0.54, 1.04)
No 1.00
Source of stem-cell graft
Bone marrow 0.72 (0.47, 1.11)
Peripheral blood 1.00
Solid circles illustrate statistically signiﬁcant associations, while open circles illustrate non-signiﬁcant ones.
Only the primary risk factors were evaluated for statistical signiﬁcance and illustrated graphically. Covariates were included if they improved the ﬁt of the model to
the data. P values were corrected for multiple hypothesis testing using the Holm–Bonferroni adjustment (Holm, 1979).
†Covariate’s effect is time-dependent, due to a change in a subject’s surveillance or to delayed onset of the risk factor.
The current study is not the ﬁrst to associate the control of
human CMV with KIRs that are evolutionarily speciﬁc for HLA-
C (Kuijpers et al., 2008; Foley et al., 2012a,b). Such KIRs present
a number of special considerations. For instance, KIR2DL2 and
KIR2DS2 are in linkage disequilibrium; as a result, our sam-
ple included few donors having one of these genes but not the
other (“discordant donors,” n = 6). Nevertheless, associations
with each of these two KIRs were so strong that they could be
detected in our sample. Current ﬁndings do not depend on the
six subjects with discordant donor, however. When those sub-
jects are omitted, the model still shows that, relative to having
neither KIR2DL2 nor KIR2DS2, having both donor genes with
ligand absent-from-genotype is associated with a 0.4-fold reduc-
tion in risk of reactivation, a ﬁgure that corresponds, as it should
do, to the product of the associations we report in Table 3 for
KIR2DL2 without C1 (7.97) and KIR2DS2 without C1 (0.05).
In other words, in the absence of ligand, the combined effects
of inhibitory KIR2DL2 and activating KIR2DS2 result in a net
reduction in CMV reactivation, the 20-fold reduction in risk asso-
ciated with KIR2DS2 (rate ratio 0.05) outweighing the eightfold
increase in risk associated with KIR2DL2. Thus, despite their
partial homology, inhibitory KIR2DL2 and activating KIR2DS2
have qualitatively different effects on risk of CMV reactivation, as
KIR2DL1 and KIR2DS1 currently do also.
KIR2DS2 has reportedly lost avidity for its evolutionary lig-
and, C1 (Moesta et al., 2010). Nevertheless, in the current study
(Table 3), C1 in genotype eliminated the beneﬁt associated with
KIR2DS2 just as it eliminated the disadvantage associated with
KIR2DL2. Our genotypic data cannot reveal the mechanism
underlying this apparentKIR2DS2–C1 interaction, but the ﬁnding
suggests that, at least in the setting of CMV infection after HSCT,
binding afﬁnity of KIR2DS2 forC1may be present in vivo, perhaps
facilitated by a peptide of viral origin. C1-speciﬁc KIRs (KIR2DL2,
KIR2DL3) reportedly recognize a few C2 alleles also,most strongly
C*0501 (Graef et al., 2009). If the latter allele is included as a lig-
and for KIR2DL2 (and for its partial homolog, KIR2DS2), the
results of the current study are virtually unchanged (data not
shown). In addition, KIR2DS4 recognizes more than one ligand,
chieﬂy a C2 allele (C*0501), a C1 allele (C*1601), and A*1102 (an
allele not present among our sample; Graef et al., 2009). In our
study, because the latter three ligands are uncommon, KIR2DS4
was nearly always present without ligand-in-genotype, potentially
explaining a previously reported association between KIR2DS4
and reduced risk of CMV reactivation after HSCT (Chen et al.,
2006; Cook et al., 2006; Zaia et al., 2009; Gallez-Hawkins et al.,
2011; Stern et al., 2011).
Because KIR2DL2 and KIR2DL3 are alleles, it is possible for
one or both alleles to be present in a given donor. In our analysis,
the association with donor KIR2DL2 was unaffected by whether
KIR2DL3 was also present (data not shown), a ﬁnding consistent
with reports that KIR2DL2 is a stronger receptor for ligand C1
than is KIR2DL3 (Moesta et al., 2008, 2010; Fadda et al., 2010).
Furthermore, during NK cell development from progenitor cells,
KIR2DL1 appears later and at lower frequency than KIR2DL2 and
KIR2DL3, which dominate the early NK cell repertoire (Fischer
et al., 2007). Accordingly, current associations of CMV reacti-
vation with KIR2DL1 and its partial homolog, KIR2DS1, were
qualitatively similar to, but with later onset and lower magnitude
than, the associations of their non-time-dependent counterparts,
KIR2DL2 and KIR2DS2.
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Under the arming model (Raulet and Vance, 2006), NK cells
are hyporesponsive by default and become responsive upon inter-
action between inhibitory KIR and ligand. In contrast, under the
disarmingmodel (Raulet andVance, 2006),NK cells are responsive
by default and become hyporesponsive from lack of interaction
between inhibitory KIR and ligand. Our own observations are
more consistent with the latter model, with the difference that,
in our study, disarming applies to activating as well as inhibitory
KIRs, which in turn exert qualitatively different effects on con-
trol of CMV after HLA-matched HSCT. Speciﬁcally, inhibitory
KIR without HLA interaction results in inferior outcome (greater
incidence of CMV reactivation), while activating KIR without
HLA interaction results in superior outcome (lower incidence of
reactivation) among our subjects.
Taken together, our observations suggest that, at least in the ﬁrst
100 days after HLA-matched HSCT, the HLA ligand, rather than
providing a license for function, serves as a gatekeeper of inherent
NK cell activity: with ligand, KIR-mediated activity is held in
check, while without ligand, KIR-mediated activity is unrestricted.
Moreover, this “gatekeeping” applies to inhibitory and activating
KIRs alike, the only difference being that inhibitory KIR’s inher-
ent activity is harmful to host control of CMV, while activating
KIR’s effect is beneﬁcial, apparently promoting viral clearance.
It is possible that this gatekeeping concept can be exploited in the
development of NK-based cell therapyor inpredicting a transplant
recipient’s risk of CMV reactivation.
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